1. Home
  2. HTGC vs NRIX Comparison

HTGC vs NRIX Comparison

Compare HTGC & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hercules Capital Inc.

HTGC

Hercules Capital Inc.

HOLD

Current Price

$16.10

Market Cap

2.9B

Sector

Finance

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$23.24

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTGC
NRIX
Founded
2003
2009
Country
United States
United States
Employees
50
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.5B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
HTGC
NRIX
Price
$16.10
$23.24
Analyst Decision
Buy
Strong Buy
Analyst Count
7
12
Target Price
$18.86
$30.50
AVG Volume (30 Days)
1.4M
1.2M
Earning Date
05-05-2026
04-08-2026
Dividend Yield
12.13%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,987,000.00
Revenue This Year
$11.18
N/A
Revenue Next Year
$5.24
$48.05
P/E Ratio
$8.61
N/A
Revenue Growth
N/A
99.31
52 Week Low
$13.70
$8.20
52 Week High
$19.67
$25.09

Technical Indicators

Market Signals
Indicator
HTGC
NRIX
Relative Strength Index (RSI) 55.99 59.03
Support Level $15.17 $14.63
Resistance Level $16.39 $24.98
Average True Range (ATR) 0.28 1.23
MACD -0.02 -0.26
Stochastic Oscillator 60.45 53.44

Price Performance

Historical Comparison
HTGC
NRIX

About HTGC Hercules Capital Inc.

Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Share on Social Networks: